# Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

> **NCT06564584** · PHASE2 · RECRUITING · sponsor: **OrsoBio, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Hypertriglyceridemia
- Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** TLC-2716 Dose 1
- **DRUG:** TLC-2716 Dose 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06564584
- **Lead sponsor:** OrsoBio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2025-06
- **Final completion:** 2025-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564584, "Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06564584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*